Raymond Birge, PhD
Dr. Raymond Birge is a Professor and Vice Chair for Research in the Department of Microbiology, Biochemistry and Molecular Biology at Rutgers, the State University of New Jersey. Dr. Birge’s research focuses on apoptosis and cancer biology, focusing on genes and signaling pathways that promote tumor progression, metastasis, and immune escape. Dr. Birge also has joint appointments at The New Jersey Medical School Cancer Center and The Cancer Institute of New Jersey. He currently serves on the Board of Directors of the International Cell Death Society. Dr. Birge has authored over 90 scientific publications and serves on the editorial board of The Journal of Biological Chemistry, Frontiers in Immunology, and he is the Editor-in-Chief for Cell Communication and Signaling. Dr. Birge completed his Ph.D. in Biochemical Toxicology from the University of Connecticut and his postdoctoral training at the Rockefeller University in New York.
William Welsh, PhD
Dr. William Welsh is the Norman H. Edelman Professor in Bioinformatics at the Robert Wood Johnson Medical School at Rutgers, the State University of New Jersey. He also serves as the Director of the Division of Cheminformatics and Biomedical Informatics at the Rutgers-Cancer Institute of New Jersey. Dr. Welsh’s laboratory specializes in the development and application of computational tools for predictive toxicology and pharmaceutical drug discovery. Dr. Welsh has published over 400 articles in peer-reviewed books and journals and is credited with over 50 patents and patent applications. In 2007, he founded Snowdon, Inc., a start-up company specializing in cheminformatic tools and techniques and in the discovery and development of therapeutic agents for the treatment of cancer, pain, and infectious diseases. Dr. Welsh earned his Ph.D. in Theoretical Physical Chemistry from the University of Pennsylvania.
Youyi Peng, PhD
Dr. Youyi Peng is a Bioinformatics Specialist in the Biomedical Informatics Shared Resources of the Rutgers Cancer Institute of New Jersey, which works to translate preclinical studies in cancer drug development into clinical anti-cancer therapeutics. Previously, Dr. Peng worked for years at Intra-Cellular Therapies Inc., a biopharmaceutical company developing innovative treatments for neuropsychiatric and neurologic disorders. Dr. Peng has extensive experience in ligand-based drug design and structure-based drug design, and has authored over 15 peer-reviewed articles and generated over 12 issued patents and patent applications. Dr. Peng earned her Ph.D. in Pharmacology and Bioinformatics at Robert Wood Johnson Medical School of Rutgers, The State University of New Jersey.